NASDAQ:APTO

Aptose Biosciences (APTO) Stock Forecast, Price & News

$3.05

-0.06 (-1.93%)

(As of 09/22/2023 ET)

Compare

Today's Range: $3.02
▼
$3.21
50-Day Range: $3.04
▼
$5.04
52-Week Range: $2.91
▼
$11.85

Volume: 36,714 shs
Average Volume: 27,728 shs
Market Capitalization: $22.27 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $38.50

Aptose Biosciences MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,162.3% Upside
$38.50 Price Target
Short Interest: Healthy
1.78% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.99
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($8.65) to ($7.14) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.70 out of 5 stars

Medical Sector

91st out of 963 stocks

Biological Products, Except Diagnostic Industry

9th out of 159 stocks

4.5

Analyst's Opinion

Consensus Rating
Aptose Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $38.50, Aptose Biosciences has a forecasted upside of 1,162.3% from its current price of $3.05.
Amount of Analyst Coverage
Aptose Biosciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

5.0

Short Interest

Percentage of Shares Shorted
1.78% of the float of Aptose Biosciences has been sold short.
Short Interest Ratio / Days to Cover
Aptose Biosciences has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Aptose Biosciences has recently decreased by 7.13%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Aptose Biosciences does not currently pay a dividend.
Dividend Growth
Aptose Biosciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for APTO.

3.3

News and Social Media Coverage

News Sentiment
Aptose Biosciences has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Aptose Biosciences this week, compared to 1 article on an average week.
Search Interest
Only 2 people have searched for APTO on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
6 people have added Aptose Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Aptose Biosciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.53% of the stock of Aptose Biosciences is held by insiders.
Percentage Held by Institutions
Only 1.07% of the stock of Aptose Biosciences is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Aptose Biosciences are expected to grow in the coming year, from ($8.65) to ($7.14) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Aptose Biosciences is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Aptose Biosciences is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Aptose Biosciences has a P/B Ratio of 0.50. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Aptose Biosciences (NASDAQ:APTO) Stock

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

APTO Price History

30 days | 90 days | 365 days | Advanced Chart

APTO Stock News Headlines

September 21, 2023 | americanbankingnews.com

Short Interest in Aptose Biosciences Inc. (NASDAQ:APTO) Decreases By 7.1%

September 8, 2023 | finance.yahoo.com

Companies Like Aptose Biosciences (TSE:APS) Could Be Quite Risky

September 24, 2023 | Behind the Markets (Ad)

Buy THIS stock before Taiwan is attacked

... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.

September 7, 2023 | finance.yahoo.com

HANMI FILES EARLY WARNING REPORT IN RESPECT OF APTOSE BIOSCIENCES INC.

September 7, 2023 | markets.businessinsider.com

Expert Ratings for Aptose Biosciences

August 24, 2023 | finance.yahoo.com

Aptose to Present at the H.C. Wainwright 25th Annual Global Investment Conference

August 23, 2023 | theglobeandmail.com

Closing Bell: Aptose Biosciences Inc down on Tuesday (APS)

August 18, 2023 | fool.com

Aptose Biosciences (NASDAQ: APTO)

September 24, 2023 | Legacy Research (Ad)

WARNING: Mandatory U.S. Dollar Recall is Weeks Away

If you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.

August 11, 2023 | markets.businessinsider.com

RBC Capital Maintains Outperform Rating for Aptose Biosciences: Here's What You Need To Know

August 11, 2023 | msn.com

Aptose Biosciences GAAP EPS of -$2.27 misses by $0.34

August 2, 2023 | msn.com

Aptose Biosciences (APTO) Price Target Increased by 1614.75% to 62.90

July 28, 2023 | finance.yahoo.com

Aptose to Report Second Quarter 2023 Financial Results and Hold Conference Call on Thursday, August 10, 2023

June 27, 2023 | finance.yahoo.com

APTO - Aptose Biosciences Inc.

June 26, 2023 | finance.yahoo.com

Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance

June 12, 2023 | marketwatch.com

Aptose Shares Up 11% After Study Presentation, Analysts' Target Boosts

June 12, 2023 | benzinga.com

Oppenheimer Maintains Outperform on Aptose Biosciences, Raises Price Target to $50

June 12, 2023 | benzinga.com

Aptose Biosciences shares are trading higher after multiple firms raised their respective price targets.

June 10, 2023 | markets.businessinsider.com

JonesTrading Keeps Their Buy Rating on Aptose Biosciences (APTO)

June 5, 2023 | msn.com

Aptose Biosciences updates on reverse stock split

May 24, 2023 | finanznachrichten.de

Aptose Biosciences, Inc.: Aptose Biosciences Announces Results of Annual and Special Meeting of Shareholders

May 17, 2023 | marketwatch.com

Caspase 3 Market Business Overview and Growth Forecast by 2030

May 13, 2023 | theglobeandmail.com

Closing Bell: Aptose Biosciences Inc down on Friday (APS)

May 9, 2023 | msn.com

Aptose Biosciences GAAP EPS of -$0.15 misses by $0.03

May 9, 2023 | markets.businessinsider.com

Analyst Expectations for Aptose Biosciences's Future

May 9, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Its Buy Rating for Aptose Biosciences (APTO)

April 28, 2023 | marketwatch.com

Diffuse Large B Cell Lymphoma Drug Market Outlook by 2031

See More Headlines

Receive APTO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptose Biosciences and its competitors with MarketBeat's FREE daily newsletter.

APTO Company Calendar

Last Earnings: 8/10/2023
Today: 9/24/2023
Next Earnings (Estimated): 11/07/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:APTO
CUSIP: N/A
CIK: 882361
Web: www.aptose.com
Phone: 858-926-2730
Fax: 905-234-2120
Employees: 31
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $38.50
High Stock Price Forecast: $120.00
Low Stock Price Forecast: $12.00
Forecasted Upside/Downside: +1,162.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($7.8173)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-41,820,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -153.08%
Return on Assets: -109.40%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.11
Quick Ratio: 2.11

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.13 per share
Price / Book: 0.50

Miscellaneous

Outstanding Shares: 7,300,000
Free Float: 6,604,000
Market Cap: $22.27 million
Optionable: Optionable
Beta: 1.38

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Dr. William G. Rice Ph.D. (Age 59)
Chairman, Pres & CEO

Mr. Gregory K. Chow CPA (Age 45)
MBA, BA, Sr. VP, CFO & Principal Accounting Officer

Mr. Ernest Kitt B.S.
M.S, VP of Devel. & Technical Operations

Dr. Stephen B. Howell (Age 73)
Chief Medical Officer

Mr. Peter Murray
Director of Clinical Devel.

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

APTO Stock - Frequently Asked Questions

Should I buy or sell Aptose Biosciences stock right now?: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aptose Biosciences in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" APTO shares.
View APTO analyst ratings or view top-rated stocks.
What is Aptose Biosciences' stock price forecast for 2023?: 6 Wall Street research analysts have issued 1-year target prices for Aptose Biosciences' stock. Their APTO share price forecasts range from $12.00 to $120.00. On average, they predict the company's stock price to reach $38.50 in the next twelve months. This suggests a possible upside of 1,162.3% from the stock's current price.
View analysts price targets for APTO or view top-rated stocks among Wall Street analysts.
How have APTO shares performed in 2023?: Aptose Biosciences' stock was trading at $8.70 on January 1st, 2023. Since then, APTO shares have decreased by 64.9% and is now trading at $3.05.
View the best growth stocks for 2023 here.
Are investors shorting Aptose Biosciences?: Aptose Biosciences saw a decline in short interest in August. As of August 31st, there was short interest totaling 37,800 shares, a decline of 7.1% from the August 15th total of 40,700 shares. Based on an average daily trading volume, of 46,400 shares, the days-to-cover ratio is presently 0.8 days. Currently, 1.8% of the shares of the company are sold short.
View Aptose Biosciences' Short Interest.
When is Aptose Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our APTO earnings forecast.
How were Aptose Biosciences' earnings last quarter?: Aptose Biosciences Inc. (NASDAQ:APTO) posted its quarterly earnings results on Thursday, August, 10th. The biotechnology company reported ($2.27) EPS for the quarter, missing analysts' consensus estimates of ($2.09) by $0.18.
When did Aptose Biosciences' stock split?: Aptose Biosciences shares reverse split before market open on Tuesday, June 6th 2023. The 1-15 reverse split was announced on Tuesday, June 6th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, June 6th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What is William G. Rice, Ph.D.'s approval rating as Aptose Biosciences' CEO?: 8 employees have rated Aptose Biosciences Chief Executive Officer William G. Rice, Ph.D. on Glassdoor.com. William G. Rice, Ph.D. has an approval rating of 34% among the company's employees. This puts William G. Rice, Ph.D. in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 52.0% of employees surveyed would recommend working at Aptose Biosciences to a friend.
What other stocks do shareholders of Aptose Biosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Aptose Biosciences investors own include Aurinia Pharmaceuticals (AUPH), Arch Therapeutics (ARTH), Aurora Cannabis (ACB), NVIDIA (NVDA), Advanced Micro Devices (AMD), Anavex Life Sciences (AVXL), CymaBay Therapeutics (CBAY), Cisco Systems (CSCO), Micron Technology (MU) and SCYNEXIS (SCYX).
What is Aptose Biosciences' stock symbol?: Aptose Biosciences trades on the NASDAQ under the ticker symbol "APTO."
Who are Aptose Biosciences' major shareholders?: Aptose Biosciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include DRW Securities LLC (0.63%), Carlson Capital L P (0.11%), Goldman Sachs Group Inc. (0.04%) and Voss Capital LLC (0.02%). Insiders that own company stock include Denis R Burger, Donald R Jr Wilson, Erich Platzer, Rafael Bejar, Warren Whitehead and William G Rice.
View institutional ownership trends.
How do I buy shares of Aptose Biosciences?: Shares of APTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Aptose Biosciences' stock price today?: One share of APTO stock can currently be purchased for approximately $3.05.
How much money does Aptose Biosciences make?: Aptose Biosciences (NASDAQ:APTO) has a market capitalization of $22.27 million. The biotechnology company earns $-41,820,000.00 in net income (profit) each year or ($7.8173) on an earnings per share basis.
How can I contact Aptose Biosciences?: Aptose Biosciences' mailing address is 251 CONSUMERS ROAD SUITE 1105, TORONTO A6, M2J 4R3. The official website for the company is www.aptose.com. The biotechnology company can be reached via phone at 858-926-2730, via email at ir@aptose.com, or via fax at 905-234-2120.

This page (NASDAQ:APTO) was last updated on 9/24/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial